Virios Therapeutics (VIRI) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

VIRI Virios Therapeutics

Watchlist

0.159
+0.003+2.12%

Close Oct 2 16:00 ET

0.158
-0.002-0.94%

Post 20:01 ET

4.42MMarket Cap-691P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | HC Wainwright & Co. Maintains Neutral on Virios Therapeutics, Lowers Price Target to $0.2
BenzingaAug 9 17:19 ET
Virios Therapeutics Analyst Ratings
BenzingaAug 9 17:17 ET · Ratings
Buy Rating for Virios Therapeutics Amid Promising Long COVID Treatment and Legislative Tailwinds
TipRanksAug 9 13:05 ET · Ratings
Virios Therapeutics | 10-Q: Q2 2024 Earnings Report
SECAug 9 10:17 ET · Announcements
Virios Therapeutics Reports Q2 Results
Seeking AlphaAug 9 09:22 ET
Hold Rating Maintained for Virios Therapeutics Amidst Financial Uncertainty and Pipeline Prospects
TipRanksAug 9 08:17 ET · Ratings

Comments

Trytosaveabit

Aug 23 05:02

Lookin for why

$Virios Therapeutics (VIRI.US)$ 🤔

Jaguar8

Jul 23 11:38

NEWS

$Virios Therapeutics (VIRI.US)$
Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center
Virios Therapeutics (Nasdaq: VIRI) announced the completion of enrollment in a Phase 2 Long-COVID study for IMC-2, conducted by Bateman Horne Center. The study evaluates the combination of valacyclovir and celecoxib as a treatment for Long-COVID symptoms. Top line results are expected in October 2024.
The randomized, double-blind, pla...